Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy.

Détails

ID Serval
serval:BIB_1297A35C39F7
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy.
Périodique
American Journal of Transplantation
Auteur⸱e⸱s
Baid S., Tolkoff-Rubin N., Saidman S., Chung R., Williams W.W., Auchincloss H., Colvin R.B., Delmonico F.L., Cosimi A.B., Pascual M.
ISSN
1600-6135[print], 1600-6135[linking]
Statut éditorial
Publié
Date de publication
01/2003
Volume
3
Numéro
1
Pages
74-78
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Résumé
The use of interferon-alpha (IFN) in hepatitis C (HCV)-infected renal recipients has been associated with acute rejection and graft loss. We reviewed our recent experience in HCV (+) renal recipients treated with antiviral therapy for biopsy proven chronic hepatitis C. Twelve HCV (+) recipients who recently received antiviral therapy were analyzed. Post-treatment sera were tested for donor-specific human leukocyte antigen (HLA) antibodies (DSA). Within 6 months of initiating antiviral therapy, two of 12 patients (17%) developed acute rejection, which was characterized as acute humoral rejection (de novo DSA in serum and C4d deposits in peritubular capillaries). Both progressed to graft failure. Nine of the remaining 10 patients tested did not have DSA. The use of IFN was associated with severe acute humoral rejection (C4d +, DSA +). The recognition of IFN-associated acute humoral rejection in this series may explain the high rate of graft loss reported previously in renal recipients receiving IFN.
Mots-clé
Adult, Antiviral Agents/pharmacology, Female, Graft Rejection/immunology, Hepatitis C/immunology, Humans, Interferon-alpha/pharmacology, Kidney Transplantation/immunology, Male, Middle Aged, Ribavirin/pharmacology
Pubmed
Web of science
Création de la notice
29/01/2008 14:52
Dernière modification de la notice
20/08/2019 13:40
Données d'usage